Intraocular Anti-VEGF Compared With Intraocular Triamcinolone in Patients With Diabetic Macular Edema
Status:
Completed
Trial end date:
2014-07-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to investigate the change in macular edema and the absolute
change in visual acuity following intravitreal administered injections of Bevacizumab
(Avastin®) or Ranibizumab (Lucentis®) compared with Triamcinolone (Volon A®) in patients with
clinical significant diabetic macular edema.
The investigators monitor the change in macular edema measured with standard optical
coherence tomography (OCT) and the absolute change in visual acuity analyzed by standardized
charts according to the protocol used in the Early Retreatment in Diabetic Retinopathy Study
(ETDRS).